← Back to all trials
Recruiting
NCT07618936
Programmed Cell Death Ligand 1 PET/CT in Various PD-L1-Related Disease Patients
Conditions: PD-L1 Gene Mutation, PD-L1 Gene Amplification, PD-L1-related Disease, Positron Emission Tomography
Sex: All
Ages: 18 Years – 80 Years
Enrollment: 500
Sponsor: Tianjin Medical University
Location: The First Affiliated Hospital of University of Science and Technology of China Hefei Anhui
Summary
To evaluate the potential usefulness of 68Ga/18F-PD-L1 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various PD-L1-related disease patients
Eligibility Criteria
Inclusion Criteria:
* (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled PD-L1 PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
Exclusion Criteria:
* (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Source: ClinicalTrials.gov (NCT07618936). StuddyBuddy aggregates publicly available trial information.